Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Accounts Payables (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Accounts Payables for 16 consecutive years, with $608833.0 as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 67.65% to $608833.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $608833.0, a 67.65% decrease, with the full-year FY2025 number at $608833.0, down 67.65% from a year prior.
  • Accounts Payables was $608833.0 for Q4 2025 at Cryo Cell International, down from $2.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.1 million in Q2 2023 to a low of $426002.0 in Q4 2021.
  • A 5-year average of $1.9 million and a median of $1.9 million in 2022 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: surged 603.84% in 2023, then plummeted 67.65% in 2025.
  • Cryo Cell International's Accounts Payables stood at $426002.0 in 2021, then increased by 5.88% to $451037.0 in 2022, then surged by 603.84% to $3.2 million in 2023, then crashed by 40.71% to $1.9 million in 2024, then tumbled by 67.65% to $608833.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Accounts Payables are $608833.0 (Q4 2025), $2.6 million (Q3 2025), and $2.2 million (Q2 2025).